The Heparan Sulfate Motif (GlcNS6S-IdoA2S)3, Common in Heparin, Has a Strict Topography and Is Involved in Cell Behavior and Disease-Reference-Cited by-同舟云学术

The Heparan Sulfate Motif (GlcNS6S-IdoA2S)3, Common in Heparin, Has a Strict Topography and Is Involved in Cell Behavior and Disease

Published:2010-12 Issue:52 Volume:285 Page:41143-41151
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Smits Nicole C.,Kurup Sindhulakshmi,Rops Angelique L.,ten Dam Gerdy B.,Massuger Leon F.,Hafmans Theo,Turnbull Jeremy E.,Spillmann Dorothe,Li Jin-ping,Kennel Stephen J.,Wall Jonathan S.,Shworak Nicholas W.,Dekhuijzen P.N. Richard,van der Vlag Johan,van Kuppevelt Toin H.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference46 articles.

1. Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate

2. Heparan sulfate fine structure and specificity of proteoglycan functions

3. Regulated Diversity of Heparan Sulfate

4. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?

5. New insights into heparin-induced FGF oligomerization

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational synthesis of a heparan sulfate saccharide that promotes the activity of BMP2;Carbohydrate Polymers;2024-06

2. VAR2HP recognizing heparin‐like epitopes in targeted therapy and diagnosis of tumors;Proteoglycan Research;2024-01

3. HS, an Ancient Molecular Recognition and Information Storage Glycosaminoglycan, Equips HS-Proteoglycans with Diverse Matrix and Cell-Interactive Properties Operative in Tissue Development and Tissue Function in Health and Disease;International Journal of Molecular Sciences;2023-01-06

4. A mutated glycosaminoglycan-binding domain functions as a novel probe to selectively target heparin-like epitopes on tumor cells;Journal of Biological Chemistry;2022-12

5. Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design;Current Pharmaceutical Design;2022-12